EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incidence and oncologic outcomes of patients with prostate‐specific antigen persistence after radical prostatectomy

Brian R Lane, Patrick Lewicki iD, Sabrina L Noyes iD, Corinne Labardee, Sabir Meah, Stephanie Daignault-Newton, Jason Hafron, Todd M Morgan, Archana Radhakrishnan, Robert T Dess iD, James Montie, Khurshid R Ghani und 2 weitere

Cancer · 15.02.2026 · 132 (4)

DOI: 10.1002/cncr.70291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 05.02.2026. Verfasst von Brian R Lane und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Corewell Health West, Grand Rapids, Michigan, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Prostate-Specific Antigen, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Betz Family Endowment for Cancer Research, AHRQ HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with postradical prostatectomy (RP) prostate‐specific antigen (PSA) persistence (PPP) have been grouped with patients experiencing biochemical recurrence (BCR) in guidelines and clinical trials, potentially masking their distinct, unfavorable outcomes. The objective of this study was to determine whether patients with PPP constitute a unique, high‐risk population.

Methods

The authors conducted a retrospective study of patients with prostate cancer undergoing RP (between January l, 2013 and June 30, 2024) using the Michigan Urological Surgery Improvement Collaborative (MUSIC) registry. Post‐RP status was defined as no evidence of disease (NED; never developed detectable PSA), PPP (first PSA remained detectable), and BCR (initially undetectable PSA with PSA ≥0.2 ng/mL later). The following differences were quantified: (1) pre‐RP characteristics, (2) pathologic characteristics at RP, (3) subsequent treatment patterns, and (4) differences in mortality outcomes based on postoperative PSA status.

Results

Of 15,390 patients with who had a follow‐up of 4.0 years (interquartile range, 2.4–4.6 years), 11,019 still had NED, 1919 had PPP, and 2452 developed BCR. Patients who had PPP demonstrated a higher risk pre‐RP and post‐RP characteristics compared with those who had NED or BCR on unadjusted and adjusted comparisons, with differences that were both statistically significant and clinically meaningful. Patients who had PP had significantly higher PSA values before secondary treatment compared with those who had BCR (median PSA, 0.73 vs. 0.28 ng/mL, respectively; p < .001). The 5‐year all‐cause mortality rate was 2.5% (95% confidence interval, 2.1%–2.9%) for patients with initially undetectable PSA (NED and BCR combined) and 5.7% (95% confidence interval, 4.3%–5.7%) for patients with PPP ( p < .001).

Conclusions

One in eight patients who undergo prostatectomy experience PPP. These patients constitute a unique, high‐risk population distinct from patients who have NED and BCR. Clinical trials addressing optimal treatment and intensity for these at‐risk patients are critically warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomyProstate-Specific AntigenNeoplasm Recurrence, LocalHumansMaleAgedRetrospective StudiesMiddle AgedIncidenceTreatment OutcomeRegistries

Stichwörter der Autor:innen

biochemical recurrence (BCR)diagnosismanagementprostate cancer

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Division of Urology, Corewell Health West, Grand Rapids, Michigan, USA.
  • Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.
  • Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Urology, Michigan Institute of Urology, Troy, Michigan, USA.
  • Department of Urology, Corewell Health East, Royal Oak, Michigan, USA.
  • Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.

ORCID-Profile: Patrick Lewicki, Sabrina L Noyes, Robert T Dess, Tudor Borza

Förderung

  • NCI NIH HHS
  • Betz Family Endowment for Cancer Research
  • AHRQ HHS
  • Corewell Health Foundation
  • Blue Cross Blue Shield of Michigan Foundation

Zitieren

APA

Lane, B. R., Lewicki, P., Noyes, S. L., Labardee, C., Meah, S., Daignault-Newton, S., Hafron, J., Morgan, T. M., Radhakrishnan, A., Dess, R. T., Montie, J., Ghani, K. R., Ginsburg, K. B., & Borza, T. (2026). Incidence and oncologic outcomes of patients with prostate‐specific antigen persistence after radical prostatectomy. Cancer, 132(4). https://doi.org/10.1002/cncr.70291

Vancouver

Lane BR, Lewicki P, Noyes SL, Labardee C, Meah S, Daignault-Newton S, et al. Incidence and oncologic outcomes of patients with prostate‐specific antigen persistence after radical prostatectomy. Cancer. 2026;132(4). doi:10.1002/cncr.70291

BibTeX
@article{Lane2026,
  author = {Lane, Brian R and Lewicki, Patrick and Noyes, Sabrina L and Labardee, Corinne and Meah, Sabir and Daignault-Newton, Stephanie and Hafron, Jason and Morgan, Todd M and Radhakrishnan, Archana and Dess, Robert T and Montie, James and Ghani, Khurshid R and Ginsburg, Kevin B and Borza, Tudor},
  title = {Incidence and oncologic outcomes of patients with prostate‐specific antigen persistence after radical prostatectomy},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {4},
  doi = {10.1002/cncr.70291}
}
Kostenlos starten →